Influence of SARS-CoV-2 mRNA Vaccine Booster among Cancer Patients on Active Treatment Previously Immunized with Inactivated versus mRNA Vaccines: A Prospective Cohort Study.

Author: BalcellsM Elvira, BarreraAldo, BroekhuizenRichard, BuenoSusan M, CabreraOlivia, CerdaValentina, CisternasBetzabé, EspinozaManuel A, FerrésMarcela, KalergisAlexis M, Le CorreNicole, Macanas-PirardPatricia, Martínez-ValdebenitoConstanza, MondacaSebastián, NerviBruno, OrmazábalIvana, PalmaSilvia, PradoMaría E, PérezPatricia, RossPatricio, Ruiz-TagleCinthya, ValdésAlejandro, VenegasMaría I, WalbaumBenjamín

Paper Details 
Original Abstract of the Article :
Cancer patients on chemotherapy have a lower immune response to SARS-CoV-2 vaccines. Therefore, through a prospective cohort study of patients with solid tumors receiving chemotherapy, we aimed to determine the immunogenicity of an mRNA vaccine booster (BNT162b2) among patients previously immunized ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10384024/

データ提供:米国国立医学図書館(NLM)

Boosting Immunity in Cancer Patients: mRNA Vaccine Effectiveness

The field of [oncology] faces challenges in protecting cancer patients from COVID-19, as their immune systems are often compromised by treatment. This study investigates the immunogenicity of an [mRNA vaccine booster (BNT162b2)] in cancer patients previously immunized with either an [inactivated (CoronaVac) or homologous (BNT162b2)] SARS-CoV-2 vaccine. The researchers found that both homologous and heterologous vaccine regimens elicited a strong humoral and cellular response after the booster, with the homologous regimen associated with higher neutralizing antibody positivity and total antibody levels. This study offers valuable insights into the effectiveness of booster doses in cancer patients.

Boosting Immunity: A Strategy for Cancer Patients

This research underscores the importance of [vaccine booster doses] in enhancing immune responses in cancer patients. The study's findings demonstrate that booster doses can significantly improve [antibody levels] and enhance [immune protection] against COVID-19. This is crucial for protecting this vulnerable population from the serious consequences of infection.

Navigating Vaccine Strategies for Cancer Patients

This research provides valuable guidance for clinicians navigating [vaccine strategies] for cancer patients. The study's findings highlight the importance of [personalized vaccine approaches] that take into account previous vaccination history and individual immune status. By understanding the nuances of vaccine responses in cancer patients, clinicians can tailor vaccination strategies to optimize immune protection.

Dr. Camel's Conclusion

This research offers a glimmer of hope for cancer patients facing the threat of COVID-19. Like a desert traveler seeking shelter from the elements, these patients require a robust immune response to protect them from infection. This study demonstrates the importance of booster doses in enhancing immune protection, providing a path to greater safety and well-being for this vulnerable population.

Date :
  1. Date Completed n.d.
  2. Date Revised 2023-08-01
Further Info :

Pubmed ID

37515009

DOI: Digital Object Identifier

PMC10384024

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.